TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04725591

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G6 Continuous Glucose Monitoring
Description: Collection of glucose data

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 Continuous Glucose Monitoring
Description: Collection of glucose data

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MEDISAFE WITH External Insulin Pump
Description: Insulin delivery

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDISAFE WITH External Insulin Pump
Description: Insulin delivery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diabeloop Software (Model predictive control)
Description: Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
Study: NCT06681480

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: figure-of-eight sham rTMS coil device
Description: rTMS is administered using the figure-of-eight sham coil, in trains with a total of 15000 pulses during 5 weekdays Device: figure-of-eight sham rTMS coil navigated rTMS over epileptogenic focus using figure-of-eight sham rTMS coil, optic navigation system
Study: NCT06680804

Intervention type: OTHER
Intervention: chance for vaginal delivery.
Description: chance for vaginal delivery in patients who had delivered by Caesarean section in first pregnancy

Intervention type: OTHER
Intervention: chance for vaginal delivery.
Description: chance for vaginal delivery in patients who had delivered by Caesarean section in first pregnancy
Study: NCT04725591

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabeloop Software (Model predictive control)
Description: Diabeloop software embeds a regulation algorithm to automatically regulate the patient's glycaemia. It takes as input glycaemia value received every 5 minutes from the CGM and patient inputs related to meals and physical activities and it calculates the amount of insulin to be delivered. It sends this information to the pump that automatically delivers this quantity.
Study: NCT06680960

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trunk stabilisation exercises
Description: This exercise program includes aerobic exercise, resistance exercise and trunk stabilisation training for eight weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory exercises
Description: This exercise program includes aerobic exercise, resistance exercise and respiratory exercise training for eight weeks.
Study: NCT04725591

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Declaration of meals
Description: Patient inputs related to meals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No declaration of meals
Description: No patient inputs related to meals

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Remote monitoring (Telemedicine)
Description: Remote follow up by care health providers team

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote monitoring (Telemedicine)
Description: Remote follow up by care health providers team
Study: NCT05536713

Intervention type: DEVICE
Intervention: Guardant SHIELD blood-based colorectal cancer screening test
Description: The Guardant SHIELD test combines a next-generation sequencing (NGS) based assay and a protein assay for the qualitative detection of colorectal cancer-derived tumor signal in the blood of patients at average risk for CRC. The Guardant SHIELD was developed at Guardant Health's clinical laboratory, a certified laboratory under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), to perform high-complexity clinical laboratory testing. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA); however, its performance has been established through a clinical trial, the ECLIPSE study (ClinicalTrials.gov Identifier: NCT04136002). The ECLIPSE clinical trial was a prospective, multi-site registration study and reached the targeted enrollment of 12,750 patients in December 2021.

Intervention type: DEVICE
Intervention: Guardant SHIELD blood-based colorectal cancer screening test
Description: The Guardant SHIELD test combines a next-generation sequencing (NGS) based assay and a protein assay for the qualitative detection of colorectal cancer-derived tumor signal in the blood of patients at average risk for CRC. The Guardant SHIELD was developed at Guardant Health's clinical laboratory, a certified laboratory under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), to perform high-complexity clinical laboratory testing. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA); however, its performance has been established through a clinical trial, the ECLIPSE study (ClinicalTrials.gov Identifier: NCT04136002). The ECLIPSE clinical trial was a prospective, multi-site registration study and reached the targeted enrollment of 12,750 patients in December 2021.

Intervention type: DEVICE
Intervention: Guardant SHIELD blood-based colorectal cancer screening test
Description: The Guardant SHIELD test combines a next-generation sequencing (NGS) based assay and a protein assay for the qualitative detection of colorectal cancer-derived tumor signal in the blood of patients at average risk for CRC. The Guardant SHIELD was developed at Guardant Health's clinical laboratory, a certified laboratory under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), to perform high-complexity clinical laboratory testing. The test has not been cleared or approved by the U.S. Food and Drug Administration (FDA); however, its performance has been established through a clinical trial, the ECLIPSE study (ClinicalTrials.gov Identifier: NCT04136002). The ECLIPSE clinical trial was a prospective, multi-site registration study and reached the targeted enrollment of 12,750 patients in December 2021.
Study: NCT05332067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omalizumab
Description: Omalizumab dose for each specific participant is based on that participant's weight and total IgE level. Omalizumab is provided by the manufacturer in two strengths:~• For Injection: 75 mg/0.5 mL and 150 mg/mL solution in a single-dose prefilled syringe

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo for omalizumab will be provided in 0.5 mL and 1 mL solution for injection in pre-filled syringes.
Study: NCT05794152

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized breakfast
Description: Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device.

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized snack
Description: Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast.

Intervention type: OTHER
Group type: OTHER
Intervention: Standardized lunch
Description: Participants will be provided with a standardized lunch 2 h after they have the standardized snack.
Study: NCT05887401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Text Messages (Yes)
Description: Participant will receive up to 5 supportive text-messages from the study staff per week.
Study: NCT04395599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cartography of air contamination, environment contamination and biological fluid by Sars-Cov2 during visceral surgery in COVID19 patients.
Description: Air sampling, operating room surfaces sampling and patients' biological fluid sampling for Sars-Cov2 quantification
Study: NCT05887401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Text Messages (Yes)
Description: Participant will receive up to 5 supportive text-messages from the study staff per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Text Messages (Yes)
Description: Participant will receive up to 5 supportive text-messages from the study staff per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Text Messages (Yes)
Description: Participant will receive up to 5 supportive text-messages from the study staff per week.
Study: NCT05916833

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hypopressive breathing
Description: Hot pack for 10min.Hypopressive breathing in sitting, lying and standing position. Hypopressive breathing 2 times/weekly, 5sec hold, 2-3reps, 1-2sets for 12 weeks. Session will be weekly progress.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: noble technique
Description: Hot pack for 10min. Noble technique in relaxed supine position 2time/weekly, 3-5sec hold, 10-15reps, 2-3sets for 12 weeks. Session will be weekly progress.
Study: NCT06471465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Drug: bevacizumab IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Drug: placebo IV
Study: NCT05887401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Text Messages (No)
Description: Participant will not receive supportive text-messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Text Messages (No)
Description: Participant will not receive supportive text-messages.
Study: NCT05883397

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HBOT
Description: Participants will be treated in a multiplace chamber (HAUX-Life-Support GmbH) for a total of 60 daily sessions, five days a week. Each session will consist of 90 minutes exposure to 100% oxygen at 2 ATA, with five-minute air breaks every 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HBOT
Description: Participants will be treated in a multiplace chamber (HAUX-Life-Support GmbH) for a total of 60 daily sessions, five days a week. Each session will consist of 90 minutes exposure to 100% oxygen at 2 ATA, with five-minute air breaks every 20 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hippocampal training
Description: Hippocampal training: This will combine physical and cognitive training. Training will be given 3 times per week, prior to the next HBOT, and more than 20 hours after the last HBOT session.
Study: NCT05887401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Text Messages (No)
Description: Participant will not receive supportive text-messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Text Messages (No)
Description: Participant will not receive supportive text-messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Text Messages (No)
Description: Participant will not receive supportive text-messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Text Messages (No)
Description: Participant will not receive supportive text-messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Text Messages (No)
Description: Participant will not receive supportive text-messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive Text Messages (No)
Description: Participant will not receive supportive text-messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lesson Delivery (Once)
Description: All behavioral lessons will be made available to participant simultaneously.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lesson Delivery (Once)
Description: All behavioral lessons will be made available to participant simultaneously.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lesson Delivery (Once)
Description: All behavioral lessons will be made available to participant simultaneously.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lesson Delivery (Once)
Description: All behavioral lessons will be made available to participant simultaneously.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lesson Delivery (Once)
Description: All behavioral lessons will be made available to participant simultaneously.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lesson Delivery (Once)
Description: All behavioral lessons will be made available to participant simultaneously.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lesson Delivery (Once)
Description: All behavioral lessons will be made available to participant simultaneously.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lesson Delivery (Once)
Description: All behavioral lessons will be made available to participant simultaneously.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lesson Delivery (Weekly)
Description: A new behavioral lesson will be made available to participant weekly throughout the 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lesson Delivery (Weekly)
Description: A new behavioral lesson will be made available to participant weekly throughout the 12 weeks.
Study: NCT04954287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVXGA1 low dose
Description: see arm/group description

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVXGA1 high dose
Description: see arm/group description

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVXGA1 high dose
Description: see arm/group description

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CVXGA1 high dose
Description: see arm/group description
Study: NCT05948787

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Psychosocial intervention
Description: A structured sessions for families that promotes improving communication, bonding, and improved parenting techniques in managing stress within the family setting.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Description: A structured sessions for families that promotes improving communication, bonding, and improved parenting techniques in managing stress within the family setting.
Study: NCT06349018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Supplement: High nitrate isotonic drink
Description: High nitrate (12.9 mmol) drink with carbohydrate and minerals

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: No nitrate isotonic drink
Description: Carbohydrate and mineral isotonic drink
Study: NCT05887401

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lesson Delivery (Weekly)
Description: A new behavioral lesson will be made available to participant weekly throughout the 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lesson Delivery (Weekly)
Description: A new behavioral lesson will be made available to participant weekly throughout the 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lesson Delivery (Weekly)
Description: A new behavioral lesson will be made available to participant weekly throughout the 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lesson Delivery (Weekly)
Description: A new behavioral lesson will be made available to participant weekly throughout the 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lesson Delivery (Weekly)
Description: A new behavioral lesson will be made available to participant weekly throughout the 12 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lesson Delivery (Weekly)
Description: A new behavioral lesson will be made available to participant weekly throughout the 12 weeks.
Study: NCT04167969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots
Description: Patients will be injected with approximately 5 mCi (+/- 10%) of a copper-64 (64Cu)-labeled PSMA-targeting particle tracer, or 64Cu-NOTA-PSMAi-PEG-Cy5.5-C' dots, up to 48 hours before surgery.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: Imaging will be performed using the GE Signa PET/MRI.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and urine sampling
Description: Staff will perform the IV blood draws and collect urine samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic radical prostatectomy and bilateral pelvic LN dissection or a salvage lymph node dissection
Description: Surgery will be performed within 24 h of the third PET/MRI scan.
Study: NCT05449119

Intervention type: BIOLOGICAL
Intervention: Fecal and blood sampling and collection of nutritional, cognitive and sensorimotor data
Description: at T0, T3 months, T6 months, T9 months and T12 months

Intervention type: BIOLOGICAL
Intervention: Fecal and blood sampling and collection of nutritional, cognitive and sensorimotor data
Description: at T0, T3 months, T6 months, T9 months and T12 months

Intervention type: OTHER
Intervention: Body Mass Index (BMI)
Description: Calculation of BMI with height measurement by heel-knee distance measurement at T0, T3 months, T6 months, T9 months and T12 months

Intervention type: OTHER
Intervention: Body Mass Index (BMI)
Description: Calculation of BMI with height measurement by heel-knee distance measurement at T0, T3 months, T6 months, T9 months and T12 months

Intervention type: OTHER
Intervention: 24-hour food and beverage record
Description: at T0, T3 months, T6 months, T9 months and T12 months

Intervention type: OTHER
Intervention: 24-hour food and beverage record
Description: at T0, T3 months, T6 months, T9 months and T12 months

Intervention type: OTHER
Intervention: Mini Nutritional assessment (MNA)
Description: at T0, T3 months, T6 months, T9 months and T12 months

Intervention type: OTHER
Intervention: Mini Nutritional assessment (MNA)
Description: at T0, T3 months, T6 months, T9 months and T12 months

Intervention type: OTHER
Intervention: Measurement of muscle mass by bioelectrical impedance analysis (except for participants with a pacemaker)
Description: at T0, T3 months, T6 months, T9 months and T12 months

Intervention type: OTHER
Intervention: Measurement of muscle mass by bioelectrical impedance analysis (except for participants with a pacemaker)
Description: at T0, T3 months, T6 months, T9 months and T12 months

Intervention type: OTHER
Intervention: Measurement of sensorimotor functions
Description: at T0, T3 months, T6 months, T9 months and T12 months

Intervention type: OTHER
Intervention: Measurement of sensorimotor functions
Description: at T0, T3 months, T6 months, T9 months and T12 months

Intervention type: OTHER
Intervention: Measurement of cognitive functions
Description: at T0, T3 months, T6 months, T9 months and T12 months

Intervention type: OTHER
Intervention: Measurement of cognitive functions
Description: at T0, T3 months, T6 months, T9 months and T12 months
Study: NCT04878341

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: The ESP is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Erector Spinae Plane Block
Description: The ESP is fascial plane block performed by injecting local anesthetic between the erector spinae muscle and the transverse process. Its proposed mechanism of action is via blockade of the dorsal and ventral rami of the thoracic spinal nerves and sympathetic fibers.
Study: NCT04066751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivacaftor
Description: Ivacaftor will be supplied as a tablet for oral administration, film-coated, 150 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ivacaftor
Description: Ivacaftor will be supplied as a tablet for oral administration, film-coated, 150 mg
Study: NCT04989322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8 mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC5 Q3W
Study: NCT05790941

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Latanoprost and Minoxidil
Description: Latanoprost and Minoxidil formulation for the treatment of hypotrichosis of the eyebrows.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Latanoprost and Minoxidil
Description: Latanoprost and Minoxidil formulation for the treatment of hypotrichosis of the eyebrows.
Study: NCT05365529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating
Description: Participants in the TRE group with continue to follow their physicians treatment plan for type II diabetes mellitus and consume all of their food within an 8-10 hour eating window.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Participants in the Standard of Care group will continue to follow their physician's treatment plan for type II diabetes mellitus.
Study: NCT06286982

Intervention type: OTHER
Intervention: Oral Symptom Assessment Scale
Description: The Oral Symptom Assessment Scale is a patient-rated oral (or mouth) symptom assessment tool
Study: NCT06434857

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength training in older adults with mild or non existent cognitive impairment
Description: Strength training program applied to strength training group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multimodal excercise in older adults with mild or non existent cognitive impairment
Description: Multimodal exercise program applied to multimodal exercise group
Study: NCT05365607

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NightWare
Description: A wearable digital therapeutic platform consisting of an Apple Watch and iPhone pre-provisioned with Nightware intervention app that will deliver a mild vibration to the watch after detecting individual having a nightmare based on Nightware proprietary algorithm, arousing the individual and disrupting nightmare without awakening.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham NightWare
Description: NightWare device will not deliver an intervention (i.e., no vibration)
Study: NCT05751200

Intervention type: OTHER
Intervention: No Intervention.
Description: No Intervention.

Intervention type: OTHER
Intervention: No Intervention.
Description: No Intervention.
Study: NCT05555108

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ACTCOM-I Intervention
Description: ACTCOM-I s an individual treatment protocol based on Acceptance and Commitment Therapy (ACT) with targeted behavioral components for insomnia treatment and a specific focus on selfcompassion as a protector for sleep disturbance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard CBT-I Intervention
Description: Standard CBT-I treatment for chronic insomnia. Treatment protocol adapted from Morin's protocol (1993)